Latest research on Olmesartan medoxomil

Olmesartan is an antihypertensive agent, which belongs to the class of medications called angiotensin II receptor blockers. It is indicated for the treatment of high blood pressure and is marketed under the name Olmetec®. The FDA label includes a black-box warning of injury and death to the fetus, so women of child-bearing age need to be warned and take the necessary precautions. Olmesartan is also contraindicated in diabetes mellitus patients taking aliskiren.

Latest findings

This finding is in good agreement with the work done by Thakkar et al29 for Olmesartan medoxomil nanosuspension. [source, 2016]
In recent years, studies have confirmed that Olmesartan medoxomil can improve endothelial function, resist thrombosis, improve tissue reconstruction, and resist oxidative stress to achieve atherosclerosis resistance [13, 25–28]. [source, 2016]
The latest research shows that Olmesartan medoxomil can better inhibit rat epididymal adipose cell hypertrophy and inflammatory reactions [29]. [source, 2016]
Therefore, we hypothesized that Olmesartan medoxomil may also reduce EAT volume, finally achieving an anti-atherosclerosis effect. [source, 2016]
This study is a prospective, single-center (Chinese PLA General Hospital, Beijing, China), open-label, randomized controlled trial of the efficacy of Olmesartan medoxomil on coronary atherosclerosis and EAT. [source, 2016]
Consecutive patients with coronary stenosis greater than 30 % and less than 70 % detected by CCTA will be randomly assigned to Olmesartan medoxomil or conventional antihypertensive medication groups (1:1 ratio). [source, 2016]
Subjects will be randomized to either Olmesartan medoxomil or conventional antihypertensive medication groups (1:1 ratio). [source, 2016]
In the Olmesartan medoxomil group, the usual recommended starting dose of Olmesartan medoxomil is 20 mg once daily when used as monotherapy in patients who are not volume-contracted. [source, 2016]
For patients requiring further reduction in blood pressure after 2 weeks of therapy, the dose of Olmesartan medoxomil may be increased to 40 mg. [source, 2016]
This trial is an open-label randomized clinical trial, so patients will randomly be assigned to Olmesartan medoxomil or conventional antihypertensive medication groups (1:1 ratio). [source, 2016]